RBC Capital Remains a Hold on Gilead Sciences (GILD)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
Reuters12d
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent ...
bovnews2d
Gilead Sciences Inc (GILD) Stock: Analyzing Its Quiet Power
Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...
bovnews7d
Gilead Sciences Inc (GILD)’s Stock Surge: What You Need to Know
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...